pharmaceuticals

automatic inspection machine

Clearside Biomedical Closes in on Secondary Offering

Clearside Biomedical Inc. (NASDAQ: CLSD) has updated its amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. It is worth noting that as Clearside ...
Read Full Story »
Medicine pills

Express Scripts Thumped by Short Seller Citron Research

Around noon on Thursday, short-seller Citron Research offered some free advice to President-Elect Donald Trump: If Trump is serious about cutting prescription drug costs, go after Express Scripts Holdings Co. ...
Read Full Story »
doctor

Recro Pharma Secondary Offering (UPDATE)

This story has been amended due to updated information from the filing. Recro Pharma Inc. (NASDAQ: REPH) saw its shares fall on Thursday after the company announced an update to ...
Read Full Story »
tired frustrated unhappy business person

Horizon Pharma Falls on Late-Stage Miss and Discontinuation

Horizon Pharma PLC (NASDAQ: HZNP) saw its shares take a big step back on Thursday after the company reported topline results from one of its late-stage trials. Specifically, the company ...
Read Full Story »
blue eye

Clearside Biomedical Prices Secondary Offering

Clearside Biomedical Inc. (NASDAQ: CLSD) has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The company expects to price its 4.94 ...
Read Full Story »
white pills

Trump’s Drug Price Comments Weigh on Biotech and Pharma ETFs and Shares

After Time named President-Elect Donald Trump Person of the Year, calling him President of the Divided States of America, there was one more ebb and flow for the state of business ...
Read Full Story »
FDA_logo

Repros Therapeutics Drops on FDA Vote

Repros Therapeutics Inc. (NASDAQ: RPRX) saw its shares take a loss on Wednesday after the company provided a key U.S. Food and Drug Administration (FDA) update. The company participated in ...
Read Full Story »
IPO

Tigenix Gears Up for IPO

TiGenix has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company has not released any pricing data, but ...
Read Full Story »
ThinkstockPhotos-481735362

Teva Shares Slide on Management Change

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares sank on Tuesday after the company announced a change in its management. The company has appointed Dipankar Bhattacharjee as chief executive for its ...
Read Full Story »
Good heart health

Reata Pharma Files for Secondary Offering

Reata Pharmaceuticals Inc. (NASDAQ: RETA) has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. The company did not disclose any pricing data, ...
Read Full Story »
FDA_logo

10 Major Pharma and FDA Catalysts Coming in December

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »
blue eye

EyeGate Pharmaceuticals Continues to Win in Mid-Stage Trial

EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) shares rose about 10% on Monday after the company announced promising data from its mid-stage trial of its leading product candidate. Specifically, the data came ...
Read Full Story »
Marijuana background leaf

GW Pharmaceuticals Shows Smaller Than Expected Q4 Loss

GW Pharmaceuticals PLC (NASDAQ: GWPH) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The company posted a net loss of $0.89 per share and $2.2 million ...
Read Full Story »
Unhealthy Person

Cempra Rises on Late-Stage Trial

Shares of Cempra Inc. (NASDAQ: CEMP) saw a handy gain early on Monday after Toyama Chemical announced that it had begun Phase 3 clinical trials with solithromycin in Japan for patients ...
Read Full Story »
Female patient on gurney

Recro Pharma Files for Secondary Offering Following Big Late-Stage Win

Recro Pharma Inc. (NASDAQ: REPH) saw its shares fall on Thursday after the company announced a secondary offering. No pricing details were given in the filing, but the offering is ...
Read Full Story »